To the Editor:

Langerhans cell histiocytosis (LCH) is currently considered a rare neoplastic disease with an inflammatory component, driven by genomic alterations in the mitogen-activating protein kinase (MAPK) pathway, including *BRAF*^V600E^, *MAP2K1* mutations and *BRAF* deletions \[[@C1], [@C2]\]. Lung involvement is frequently observed in adult LCH patients, almost exclusively in young smokers of both sexes \[[@C3]\]. The aetiology of LCH, including pulmonary LCH (PLCH), remains unknown. A viral triggering factor of LCH has long been suspected, but the results of studies are inconclusive \[[@C4], [@C5]\].

Recently, M[urakami]{.smallcaps} *et al*. \[[@C6]\] reported the detection of increased numbers of Merkel cell polyomavirus (MCPyV) DNA sequences in nonpulmonary LCH tissues compared to control tissues from Japanese patients and suggested an association of MCPyV with the presence of the *BRAF*^V600E^ mutation in LCH lesions \[[@C7]\]. MCPyV is composed of the regulatory proteins large T (LT) antigen (Ag) and small T (ST)-Ag, and structural proteins VP1 and VP2 \[[@C8]\]. MCPyV is known to be involved in the rare aggressive human skin cancer Merkel cell carcinoma (MCC), 80% of MCC tumours being positive for the MCPyV genome \[[@C8]\].

Our purpose was to investigate the potential involvement of MCPyV in PLCH. We used highly sensitive real-time PCR and immunohistochemistry (IHC) to detect the presence of MCPyV DNA sequences and LT-Ag in PLCH biopsies compared to that in control lung tissues. We also searched for an association between the presence of MCPyV DNA and MAPK mutation status of PLCH lesions.

Nine PLCH patients (eight with single-system disease; five females; mean age 47 years, range 30--61 years; all smokers) and 19 controls (14 females; mean age 65 years, range 28--86 years; nine smokers and 10 nonsmokers) were included. Grossly normal lung tissue was obtained at the time of thoracic surgery for localised lung disease ([table 1](#TB1){ref-type="table"}). The study was performed in accordance with the Helsinki Declaration and was approved by the INSERM Institutional Review Board and Ethics Committee in Paris, France (IRB number 13-130). All patients gave informed consent for the use of their information for research.

###### 

Main clinical characteristics of the nine patients with pulmonary Langerhans cell histiocytosis (PLCH) and the 19 lung control tissue patients as well as detection of Merkel cell polyoma virus by real-time PCR

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  **Sample**               **Patient^\#^**   **Sex**   **Age years**   **Associated localised lung lesions**   **VP1**   **ST**    **LT**    **Conclusion**
  ----------------------- ----------------- --------- --------------- --------------------------------------- --------- -------- ---------- ----------------
  **1**                        PLCH SS          F           59                          NA                        −        −         −          Negative

  **2**                        PLCH SS          F           60                          NA                        −        −         −          Negative

  **3**                        PLCH SS          M           30                          NA                        −        −         −          Negative

  **4**                        PLCH MS          M           35                          NA                       \+        −         −          Positive

  **5**                        PLCH SS          F           34                          NA                        −        −         −          Negative

  **6**                        PLCH SS          F           53                          NA                       \+        \+        \+         Positive

  **7**                        PLCH SS          F           61                          NA                        −        −         −          Negative

  **8**                        PLCH SS          M           52                          NA                       \+        \+        −          Positive

  **9**                        PLCH SS          M           40                          NA                        −        −         −          Negative

  **10**                       Smoker           F           72                    Adenocarcinoma                  −        \+        −          Positive

  **11**                       Smoker           M           80                    Adenocarcinoma                  −        \+        \+         Positive

  **12**                       Smoker           F           73                Squamous cell carcinoma            \+        −         −          Positive

  **13**                       Smoker           F           60                    Adenocarcinoma                  −        −         −          Negative

  **14**                       Smoker           M           66                    Adenocarcinoma                  −        −         \+         Positive

  **15**                       Smoker           F           70                    Adenocarcinoma                 \+        \+        −          Positive

  **16**                       Smoker           M           71               Secondary adenocarcinoma             −        \+        −          Positive

  **17**                       Smoker           M           59                    Adenocarcinoma                 \+        −         −          Positive

  **18**                       Smoker           M           75                    Adenocarcinoma                  −        −         \+         Positive

  **19**                      Nonsmoker         F           33                Localised benign cavity             −        −         \+         Positive

  **20**                      Nonsmoker         F           28                Localised cystic lesion             −        −         −          Negative

  **21**                      Nonsmoker         F           83                    Adenocarcinoma                 \+        −         \+         Positive

  **22**                      Nonsmoker         F           59                   Carcinoid tumour                 −        \+        −          Positive

  **23**                      Nonsmoker         F           60               Secondary adenocarcinoma            \+        \+        \+         Positive

  **24**                      Nonsmoker         F           71                Squamous cell carcinoma             −        −         −          Negative

  **25**                      Nonsmoker         F           86                    Adenocarcinoma                 \+        −         −          Positive

  **26**                      Nonsmoker         F           54               Localised bronchiectasis             −        −         −          Negative

  **27**                      Nonsmoker         F           74               Secondary adenocarcinoma             −        \+        −          Positive

  **28**                      Nonsmoker         F           55                   Carcinoid tumour                \+        \+        \+         Positive

  **MCC skin biopsies**                                     NA                         +++\                      ++\      +++\    Positive  
                                                                                        +\                      +++\      +++\              
                                                                                        ++                       +++       ++               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

Detection by real-time PCR of genes coding for VP1, small T (ST) and large T (LT) is reported with a qualitative score as follows. +: cycle threshold (Ct) values between \<40 and ≥35; ++: Ct values between \<35 and ≥30; +++: Ct values \<30. Results were considered negative (−) if there was no detection or a Ct value ≥40. MCC: Merkel cell carcinoma; SS: single-system disease; MS: multisystem disease. **^\#^**: all PLCH patients were current smokers at the time of surgical lung biopsy; NA: not applicable.

Formalin-fixed paraffin-embedded (FFPE) PLCH biopsies were immunostained with an anti-CD1a antibody (clone 010; Dako, Waldbronn, Germany) to identify lesional areas that were macrodissected for molecular biology analysis. FFPE control lung tissues were optically normal or displayed mild changes associated with smoking. We also performed IHC staining for the detection of MCPyV in PLCH and control lung lesions, using an antibody directed against MCPyV LT-Ag (clone CM2B4; Santa Cruz Biotechnology, Dallas, TX, USA). Immunostaining was performed with a BenchMark Ultra automated immunostainer (Roche-Ventana, Basel, Switzerland) according to the manufacturer\'s instructions.

DNA was extracted as previously described \[[@C9]\]. MCPyV DNA was detected by real-time PCR assays targeting genes coding for VP1, ST and LT using specific primers and probes \[[@C8]\]. Real-time DNA amplification was performed on an ABI PRISM 7500 SDS thermocycler (Thermo Fisher Scientific, Waltham, MA, USA). The results are reported as a qualitative score as described in [table 1](#TB1){ref-type="table"}. DNA from skin biopsies of three MCC lesions was used as a positive control. Fisher\'s exact test was performed to compare categorical variables between groups of patients, with p-values \<0.05 denoting statistical significance. To estimate the viral load of the MCPyV genome in lung biopsy samples, we used standard curves established for each target (*VP1*, *ST* and *LT*) with a plasmid including the full genome of MCPyV (RepMCV-R17a; Addgene, Watertown, MA, USA), using real-time PCR \[[@C10]\].

A custom-designed next-generation sequencing panel of 74 genes, including genes involved in the MAPK pathway, was used for genotyping PLCH tissue biopsies \[[@C2]\]. The exon 12 *BRAF* deletion was assessed using a custom pyrosequencing assay on a PyroMark Q48 instrument (Qiagen, Hilden, Germany) \[[@C2]\].

Using real-time PCR, the three skin MCC biopsies were positive for MCPyV genes ([table 1](#TB1){ref-type="table"}). *VP1*, *ST* and *LT* genes were found positive in, respectively, 10, 10 and eight lung specimens tested ([table 1](#TB1){ref-type="table"}). Three samples (one PLCH and two nonsmoker control lung tissues) were positive for all targets, whereas 10 specimens (six PLCH) were negative for all targets. Four lung tissues (one PLCH) were positive for two targets and the 11 remaining samples (one PLCH) expressed only one MCPyV DNA target. Taken together, three (33%) out of nine PLCH lesions, eight (89%) out of nine smoker control tissues and seven (70%) out of 10 nonsmoker control tissues were positive for at least one MCPyV DNA target. Compared to positive skin MCC biopsies, IHC staining for MCPyV LT-Ag was consistently negative in the seven available PLCH lesions as well as smoker or nonsmoker controls tissues ([figure 1](#F1){ref-type="fig"}).

![Immunohistochemistry. a) CD1a immunostaining of a lung biopsy from a patient with pulmonary Langerhans cell histiocytosis showing accumulation of large numbers of positive cells. b) Merkel cell polyomavirus large T antigen immunostaining on a serial section of the same lung biopsy showing that no positive cells were identified. c) Merkel cell polyomavirus large T antigen antibody immunostaining of a skin biopsy from a patient with cutaneous Merkel cell carcinoma demonstrating intensely positive tumour cells. Original magnification ×200. Scale bars=50 μm.](00230-2019.01){#F1}

The proportion of MCPyV DNA detected in PLCH biopsies was significantly lower than that detected in control tissues from both smokers and nonsmokers (p=0.035, Fisher\'s exact test comparing PLCH and control specimens). Median viral load ratios of the three genes *VP1, ST* and *LT* were not different comparing PLCH, smoker and nonsmoker lung tissues (Kruskal--Wallis, p=0.747).

An alteration of the MAPK pathway was identified in six (67%) out of nine PLCH lesions, including four *BRAF*^N486_P490del^ deletions and two *MAP2K1* mutations (R108W and G128D). Only one of these lesions harboured MCPyV DNA.

Our results are inconsistent with the previous study from the only group reporting on the presence of MCPyV DNA sequences in LCH lesions. The authors reported that 12 (92%) out of 13 nonpulmonary LCH lesions were positive for MCPyV DNA \[[@C6]\], whereas in our study, three (33%) out of nine of PLCH lesions contained DNA for at least one MCPyV target. Furthermore, based on the same MCPyV DNA detection technique and using the same criteria as M[urakami]{.smallcaps} *et al.* \[[@C6]\], *i.e.* the presence of the *LT* target, only one PLCH lesion was positive in our study.

A main difference between PLCH and other clinical forms of LCH is that the former is strongly associated with tobacco smoking \[[@C3]\]. Strikingly, we found a lower rate of detection of MCPyV DNA in PLCH lesions compared to that in smoking control lung tissues. M[urakami]{.smallcaps} *et al.* \[[@C6]\] found similar numbers of single-system and multisystem nonpulmonary LCH lesions harbouring MCPyV DNA. Thus, the fact that our series comprised almost exclusively single-system PLCH probably does not explain the discrepancy between the two studies. Furthermore, we could not confirm that the detection of MCPyV DNA was linked to the MAPK status of LCH lesions.

A possible explanation of these discordant results could be linked to ethnicity difference. Indeed, MCPyV epidemiology varies according to the ethnicity and geographic location of the subjects studied \[[@C11]\]. Consistently, discordant results for pathogen detection have been previously reported between Japanese and Caucasian patients in different diseases \[[@C12], [@C13]\].

The presence of MCPyV DNA in tested control lung tissues, regardless of the smoking status, is in accordance with what has been previously reported, although at a lower proportion (10--50%), considering either *LT* only \[[@C14]\], or *VP1* and *LT* targets \[[@C15], [@C16]\]. The fact that we also tested for the *ST* target probably explains the higher rate of positive control lung tissue samples in our series.

In summary, our results do not support the involvement of MCPyV in the pathogenesis of PLCH. Additional studies that include patients of different ethnicities, geographical areas and LCH subtypes are needed to further clarify the potential involvement of MCPyV in LCH.
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